Daily morphine administration increases impulsivity in rats responding under a 5-choice serial reaction time task.

Autor: Maguire, DR¹, Henson, C¹, France, CP^1,2, Maguire, D R³ (AUTHOR), France, C P^3,4 (AUTHOR)

Publikováno v: British Journal of Pharmacology. Apr2016, Vol. 173 Issue 8, p1350-1362. 13p. 2 Diagrams, 3 Charts, 3 Graphs.

Pharmacologic profile of ITI-333: a novel molecule for treatment of substance use disorders.

Autor: Snyder GL; Intra-Cellular Therapies Inc., 430 East 29th Street, Suite 900, New York, NY, 10016, USA. gsnyder@itci-inc.com., Li P; Intra-Cellular Therapies Inc., 430 East 29th Street, Suite 900, New York, NY, 10016, USA., Martin T; Intra-Cellular Therapies Inc., 430 East 29th Street, Suite 900, New York, NY, 10016, USA., Zhang L; Intra-Cellular Therapies Inc., 430 East 29th Street, Suite 900, New York, NY, 10016, USA., Yao W; Intra-Cellular Therapies Inc., 430 East 29th Street, Suite 900, New York, NY, 10016, USA., Zheng H; Intra-Cellular Therapies Inc., 430 East 29th Street, Suite 900, New York, NY, 10016, USA., Maguire DR; University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive (Mail Code 7764), San Antonio, TX, 78229-3900, USA.; Addiction Research, Treatment and Training Center of Excellence, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA., Gerak LR; University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive (Mail Code 7764), San Antonio, TX, 78229-3900, USA.; Addiction Research, Treatment and Training Center of Excellence, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA., Vanover KE; Engrail Therapeutics, San Diego, CA, 92130, USA., France CP; University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive (Mail Code 7764), San Antonio, TX, 78229-3900, USA.; Addiction Research, Treatment and Training Center of Excellence, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA., Davis R; Intra-Cellular Therapies Inc., 430 East 29th Street, Suite 900, New York, NY, 10016, USA.

Publikováno v: Psychopharmacology [Psychopharmacology (Berl)] 2024 Jul; Vol. 241 (7), pp. 1477-1490. Date of Electronic Publication: 2024 May 06.

Interactions between lorcaserin and opioids: Ventilation and food-versus-drug choice.

Autor: Maguire DR; Department of Pharmacology and Addiction Research, Treatment & Training Center of Excellence, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr., San Antonio, TX 78229, USA. Electronic address: maguired@uthscsa.edu.

Publikováno v: Pharmacology, biochemistry, and behavior [Pharmacol Biochem Behav] 2024 Jan; Vol. 234, pp. 173673. Date of Electronic Publication: 2023 Nov 10.

Behavioral pharmacology of methocinnamox: A potential new treatment for opioid overdose and opioid use disorder.

Autor: Maguire DR; Department of Pharmacology, University of Texas Health Science Center at San Antonio, TX, United States.; Addiction Research, Treatment, and Training Center of Excellence, University of Texas Health Science Center at San Antonio, TX, United States., France CP; Department of Pharmacology, University of Texas Health Science Center at San Antonio, TX, United States.; Addiction Research, Treatment, and Training Center of Excellence, University of Texas Health Science Center at San Antonio, TX, United States.; Department of Psychiatry, University of Texas Health Science Center at San Antonio, TX, United States.

Publikováno v: Journal of the experimental analysis of behavior [J Exp Anal Behav] 2023 Mar; Vol. 119 (2), pp. 392-406. Date of Electronic Publication: 2023 Feb 09.

OREX-1038: a potential new treatment for pain with low abuse liability and limited adverse effects.

Autor: Gerak LR; Department of Pharmacology, University of Texas Health Science Center at San Antonio.; Addiction Research, Treatment & Training Center of Excellence, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA., Maguire DR; Department of Pharmacology, University of Texas Health Science Center at San Antonio.; Addiction Research, Treatment & Training Center of Excellence, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA., Cami-Kobeci G; Department of Pharmacy and Pharmacology, University of Bath, Bath.; Current address: School of Life Sciences, University of Bedfordshire, Luton, UK., Olson KM; Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan, USA., Traynor JR; Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan, USA., Husbands SM; Department of Pharmacy and Pharmacology, University of Bath, Bath.; Centre for Therapeutic Innovation, University of Bath, Bath, UK., France CP; Department of Pharmacology, University of Texas Health Science Center at San Antonio.; Addiction Research, Treatment & Training Center of Excellence, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.; Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, Texas., Acevedo L; Orexigen Therapeutics Inc., La Jolla, California, USA., Belli B; Orexigen Therapeutics Inc., La Jolla, California, USA., Flynn P; Orexigen Therapeutics Inc., La Jolla, California, USA.

Publikováno v: Behavioural pharmacology [Behav Pharmacol] 2022 Sep 01; Vol. 33 (6), pp. 377-394. Date of Electronic Publication: 2022 Aug 03.